Gossamer Bio, Inc. (GOSS)
0.2051
+0.03
(+17.20%)
USD |
NASDAQ |
Aug 25, 16:00
0.2051
0.00 (0.00%)
After-Hours: 16:01
Gossamer Bio Enterprise Value : 68.59M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 68.59M |
| August 21, 2026 | 58.67M |
| August 20, 2026 | 60.04M |
| August 19, 2026 | 59.60M |
| August 18, 2026 | 53.00M |
| August 17, 2026 | 51.48M |
| August 14, 2026 | 58.42M |
| August 13, 2026 | 66.29M |
| August 12, 2026 | 69.86M |
| August 11, 2026 | 71.91M |
| August 10, 2026 | 69.13M |
| August 07, 2026 | 70.06M |
| August 06, 2026 | 70.25M |
| August 05, 2026 | 69.91M |
| August 04, 2026 | 71.77M |
| August 03, 2026 | 67.91M |
| July 31, 2026 | 65.90M |
| July 30, 2026 | 70.20M |
| July 29, 2026 | 84.09M |
| July 28, 2026 | 83.30M |
| July 27, 2026 | 80.52M |
| July 24, 2026 | 49.53M |
| July 23, 2026 | 52.70M |
| July 22, 2026 | 53.73M |
| July 21, 2026 | 58.72M |
| Date | Value |
|---|---|
| July 20, 2026 | 51.97M |
| July 17, 2026 | 66.19M |
| July 16, 2026 | 66.39M |
| July 15, 2026 | 62.09M |
| July 14, 2026 | 51.53M |
| July 13, 2026 | 53.48M |
| July 10, 2026 | 66.00M |
| July 09, 2026 | 68.59M |
| July 08, 2026 | 65.66M |
| July 07, 2026 | 69.81M |
| July 06, 2026 | 78.32M |
| July 02, 2026 | 67.71M |
| July 01, 2026 | 65.02M |
| June 30, 2026 | 63.51M |
| June 29, 2026 | 142.21M |
| June 26, 2026 | 140.57M |
| June 25, 2026 | 142.49M |
| June 24, 2026 | 143.38M |
| June 23, 2026 | 143.94M |
| June 22, 2026 | 142.26M |
| June 18, 2026 | 143.15M |
| June 17, 2026 | 145.73M |
| June 16, 2026 | 143.08M |
| June 15, 2026 | 142.91M |
| June 12, 2026 | 141.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| United Therapeutics Corp. | 19.23B |
| Arbutus Biopharma Corp. | 938.70M |
| Kura Oncology, Inc. | 608.46M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 16.90M |
| Revenue (Quarterly) | 9.238M |
| Total Expenses (Quarterly) | -7.662M |
| EPS Diluted (Quarterly) | -0.0766 |
| Gross Profit Margin (Quarterly) | 97.27% |
| Earnings Yield | -339.3% |
| Normalized Earnings Yield | -379.52 |